Abstract
ObjectivesTo evaluate the efficacy and safety of Yokukansan (TJ-54) in patients undergoing surgery. MethodsEfficacy was assessed by the onset of delirium, delirium rating scales, anxiety evaluated by Hospital Anxiety and Depression Scale-Anxiety (HADS-A) score, and safety was assessed by any reported adverse events. ResultsSix studies were included. There were no significant differences between the groups in the onset of delirium (risk ratio 1.15, 95% confidence interval [CI] 0.77–1.72), delirium rating scales (early postoperative period: standardized mean difference [SMD] −0.24, 95% CI −1.11 to 0.63; late postoperative period: SMD −0.06, 95% CI −1.56 to 1.45), HADS-A score (mean difference −0.47, 95% CI −1.90 to 0.96), and any adverse events (risk ratio 1.18, 95% CI 0.35–4.00). ConclusionsThe use of TJ-54 in patients undergoing surgery is not an effective strategy for postoperative delirium and anxiety. Further research considering target patients and durations of administration should be conducted.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
